NevroNVRO
NVRO
About: Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Employees: 1,215
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
45% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 38
1.36% less ownership
Funds ownership: 102.92% [Q2] → 101.56% (-1.36%) [Q3]
14% less funds holding
Funds holding: 151 [Q2] → 130 (-21) [Q3]
34% less capital invested
Capital invested by funds: $319M [Q2] → $212M (-$107M) [Q3]
43% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 40
95% less call options, than puts
Call options by funds: $434K | Put options by funds: $8.03M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
15%
downside
Avg. target
$5.09
9%
upside
High target
$7
50%
upside
8 analyst ratings
0 positive
0%
6 neutral
75%
2 negative
25%
Truist Securities Richard Newitter 81% 1-year accuracy 34 / 42 met price target | 0%upside $4.70 | Hold Maintained | 18 Dec 2024 |
Citigroup Joanne Wuensch 64% 1-year accuracy 30 / 47 met price target | 7%upside $5 | Neutral Maintained | 11 Dec 2024 |
Wells Fargo Nathan Treybeck 50% 1-year accuracy 2 / 4 met price target | 15%downside $4 | Equal-Weight Maintained | 11 Dec 2024 |
Canaccord Genuity William Plovanic 74% 1-year accuracy 34 / 46 met price target | 15%downside $4 | Hold Maintained | 9 Dec 2024 |
Morgan Stanley Cecilia Furlong 60% 1-year accuracy 3 / 5 met price target | 15%downside $4 | Underweight Downgraded | 2 Dec 2024 |
Financial journalist opinion
Based on 4 articles about NVRO published over the past 30 days
Neutral
PRNewsWire
16 hours ago
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro.
Negative
Zacks Investment Research
6 days ago
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.
Neutral
PRNewsWire
1 week ago
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif. , Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results.
Positive
Zacks Investment Research
4 weeks ago
What Makes Nevro (NVRO) a New Buy Stock
Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
1 month ago
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro.
Positive
Zacks Investment Research
1 month ago
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
NVRO's continued technological innovations and business diversification plans raise optimism about the stock.
Positive
Zacks Investment Research
1 month ago
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX.
Neutral
Benzinga
1 month ago
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
Positive
Zacks Investment Research
2 months ago
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Neutral
PRNewsWire
2 months ago
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Furthering Nevro's body of evidence as an innovation leader in pain management, da ta highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif. , Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research , which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system.
Charts implemented using Lightweight Charts™